Clinical Trial Update: A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability results for ferric citrate (Zerenex) in patients with end-stage renal disease and hyperphosphatemia; the trial is completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• Zerenex (ferric citrate)

Snippet

Sponsor: Keryx Biopharmaceuticals | Conditions: Hyperphosphatemia, End-stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-10-09